Comparable efficacy of pantoprazole and omeprazole in patients with moderate to severe reflux esophagitis: Results of a multinational study

Digestion

Volumn 67, Issue 1-2, 2003, Pages 6-13

  Körner, Thomas ^a   Schutze K ^b   Van Leendert, R J M ^c   Fumagalli, I ^d   Costa Neves, B ^e   Bohuschke, M ^f   Gatz, G ^f  

^a Zentralklinikum Suhl   (Germany)

^b HANUSCH HOSPITAL   (Austria)

^c ALBERT SCHWEITZER HOSPITAL   (Netherlands)

^d Medical Centre   (Switzerland)

^e Hospital de Pulido   (Portugal)

^f ALTANA PHARMA AG   (Germany)

Author keywords

Acid related Disease; Esophagitis; Gastroesophageal reflux disease; Omeprazole; Pantoprazole; Proton pump inhibitor

Indexed keywords

OMEPRAZOLE; PANTOPRAZOLE;

ADULT; AGED; ARTICLE; AUSTRALIA; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; ERUCTATION; FEMALE; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL ENDOSCOPY; GASTROINTESTINAL SYMPTOM; GERMANY; HEADACHE; HEALING; HEARTBURN; HELICOBACTER PYLORI; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NETHERLANDS; PAIN; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; REFLUX ESOPHAGITIS; SWITZERLAND;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ANTI-ULCER AGENTS; BENZIMIDAZOLES; CONFIDENCE INTERVALS; DOUBLE-BLIND METHOD; ESOPHAGITIS, PEPTIC; ESOPHAGOSCOPY; FEMALE; GASTROESOPHAGEAL REFLUX; HUMANS; MALE; MIDDLE AGED; OMEPRAZOLE; PROSPECTIVE STUDIES; PROTON PUMPS; SAFETY; SULFOXIDES; THERAPEUTIC EQUIVALENCY; TREATMENT OUTCOME;

EID: 17644437915     PISSN: 00122823     EISSN: None     Source Type: Journal    
DOI: 10.1159/000070201     Document Type: Article

References (35)

1. Revicki DA, Wood M, Maton PN, Sorensen S: The impact of gastroesophageal reflux disease on health-related quality of life. Am J Med 1998;104:252-258.
2. Kaplan-Machlis B, Spiegler GB, Revicki DA: Health-related quality of life in primary care patients with gastroesophagel reflux disease. Ann Pharmacother 1999;33:1032-1036.
3. Bell NJ, Burget D, Howden CW, Wilkinson J, Hunt RH: Appropriate acid suppression for the management of gastro-oesophageal reflux disease. Digestion 1992;51(suppl 1):59-67.
4. Vaezi MF, Richter JE: Gastroesophageal reflux disease. Curr Opin Gastroenterol 1993;13:327-332.
5. Dammann HG, von Kleist DH: Efficacy and tolerability of pantoprazole and ranitidine and famotidine in patients with gastro-oesophageal reflux disease: Multicentre, open, randomized, controlled studies. Intern Pract Ser 1997;15:23-29.
6. van Zyl JH, de K Grundling H, van Rensburg CJ, Retief FJ, O'Keefe SJ, Theron I, Fischer R, Bethke T: Efficacy and tolerability of 20 mg pantoprazole versus 300 mg ranitidine in patients with mild reflux-oesophagitis: A randomized, double-blind, parallel, and multi-centre study. Eur J Gastroenterol Hepatol 2000;12:197-202.
7. Dettmer A, Vogt R, Sielaff F, Lühmann R, Schneider A, Fischer R: Pantoprazole 20 mg is effective for relief of symptoms and healing of lesions in mild reflux oesophagitis. Aliment Pharmacol Ther 1998;12:865-872.
8. Kaspari S, Biedermann A, Mey J: Comparison of pantoprazole 20 mg to ranitidine 150 mg b.i.d. in the treatment of mild gastroesophageal reflux disease. Digestion 2001;63:163-170.
9. van Rensburg CJ, Bardhan KD: No clinical benefit of adding cisapride to pantoprazole for treatment of gastro-oesophageal reflux disease. Eur J Gastroenterol Hepatol 2001;13:909-914.
10. Bardhan KD: The role of proton pump inhibitors in the treatment of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1995;9(suppl 1):15-25.
11. Tolman KG, Chandramouli J, Fang JC: Proton pump inhibitors in the treatment of gastro-oesophageal reflux disease. Expert Opin Pharmacother 2000;1:1171-1194.
12. Caro JJ, Salas M, Ward A: Healing and relapse in gastroesophageal reflux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine, and placebo: Evidence from randomized clinical trials. Clin Ther 2001;23:998-1017.
13. Bardhan KD, van Rensburg C: Comparable clinical efficacy and tolerability of 20 mg pantoprazole and 20 mg omeprazole in patients with grade I reflux oesophagitis. Aliment Pharmacol Ther 2001;15:1585-1591.
14. Bardhan KD: Pantoprazole: A new proton pump inhibitor in the management of upper gastrointestinal disease. Drugs Today 1999;35:773-808.
15. Langtry HD, Wilde MI: Omeprazole. A review of its use in Helicobacter pylori infection, gastro-oesophageal reflux disease and peptic ulcers induced by nonsteroidal anti-inflammatory drugs. Drugs 1998;56:447-486.
16. Bochenek W, Miska D, Beg M: Efficacy of pantoprazole in reflux erosive esophagitis (EE) is dose related (abstract). Digestion 1998;59(suppl 3):601.
17. Reill L, Erhardt F, Fischer R, Huber R, Londong W: Dose-response of pantoprazole 20, 40 and 80 mg on 24-hour intragastric pH and serum gastrin in man (abstract). Gut 1993;34(suppl 4):F251.
18. Katz PO, Paoletti V, Bochenek W, Steinberg M: A double-blind, randomized, crossover, dose-response study of the effects of 10, 20, or 40 mg of oral pantoprazole taken once daily on intragastric pH in healthy adults (abstract). Gastroenterology 1999;116:A208.
19. Bate CM, Booth SN, Crowe JP, Hepworth-Jones B, Taylor MD, Richardson PDI: Does 40 mg omeprazole daily offer additional benefit over 20 mg daily in patients requiring more than 4 weeks of treatment for symptomatic reflux oesophagitis? Aliment Pharmacol Ther 1993;7:501-507.
20. Laursen LS, Havelund T, Bondesen S, Hansen J, Sanchez G, Sebelin E, Fenger C, Lauritsen K: Omeprazole in the long-term treatment of gastro-oesophageal reflux disease. A double-blind randomized dose-finding study. Scand J Gastroenterol 1995;30:839-846.
21. Savary M, Miller G: The esophagus; in Savary M, Miller G (eds): Handbook and Atlas of Endoscopy. Solothurn, Gassmann, 1978, pp 119-205.
22. Schaltenbrand R, Huber R, Cotoraci CA, Mascher H, Potthast H, Hole U: Bioequivalence between omeprazole MUPS 20 mg tablets and omeprazole MUPS 20 mg as tablet encapsulated in a hard gelatine capsule. Int J Clin Pharmacol Ther 2001;10:453-459.
23. Dent J, Brun J, Fendrick AM, Fennerty MB, Janssens J, Kahrilas PJ, Lauritsen K, Reynolds JC, Shaw M, Talley NJ on behalf of the Genval Workshop Group: An evidence-based apparaisal of reflux disease management. The Genval Workshop Report. Gut 1999;44(suppl 2):S1-S16.
24. Galmiche JP, Bruley des Varannes S: Symptoms and disease severity in gastro-oesophageal reflux disease. Scand J Gastroenterol 1994;29(suppl 201):62-68.
25. Rothman M, Farup C, Stewart W, Helbers L, Zeldis J: Symptoms associated with gastroesophageal reflux disease. Dig Dis Sci 2001;46:1540-1548.
26. Moennikes H: Increasing the dose, evaluating compliance, revising the diagnosis. Prescriptions for apparently resistant processes in the esophagus. MMW Fortschr Med 2000;14:39-42.
27. Hungin AP, Rubin G, O'Flanagan H: Factors influencing compliance in long-term proton pump inhibitor therapy in genral practice. Br J Gen Pract 1999;49:463-464.
28. Farup PG: Compliance with anti-ulcer medicatrials. Aliment Pharmacol Ther 1992;6:179-186.
29. Fujimori T, Kawamata H, Ichikawa K, Ono Y, Okura Y, Tomita S, Imura J: Pathological issues of gastric and lower esophageal cancer: Helicobacter pylori infection and its eradication. J Gastroenterol 2002;37(suppl 13):28-33.
30. Fallone CA, Barkun AN, Gottke MU, Best LM, Loo VG, Veldhuyzen van Zanten S, et al: Association of Helicobacter pylori genotype with gastroesophageal reflux disease and other upper gastrointestinal diseases. Am J gastroenterol 2000;97:1065.
31. Malfertheiner P, O'Connor HJ, Genta RM, Unge P, Axon AT: Symposium: Helicobacter pylori and clinical risks - focus on gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2002;16(suppl 3):1-10.
32. Bazzoli F, Porro G, Bianchi MG, Molteni M, Pazzato P, Zagari RM: Treatment of Helicobacter pylori infection. Indications and regimens: An update. Dig Liver Dis 2002;34:70-83.
33. Peek RM Jr, Blaser MJ: Helicobacter pylori and gastrointestinal tract adenocarcinomas. Nat Rev Cancer 2002;2:28-37.
34. Sharma P: Helicobacter pylori: A debated factor in gastroesophageal reflux disease. Dig Dis 2001;19:127-133.
35. Labenz J, Tillenburg B, Peitz U, Idstrom JP, Verdu EF, Stolte M, Borsch G, Blum AL: Helicobacter pylori augments the pH-increasing effect of omeprazole in patients with duodenal ulcer. Gastroenterology 1996;110:947-950.